[{"orgOrder":0,"company":"Seagen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Polatuzumab Vedotin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Roche"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Five Prime Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody-drug conjugate","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Seagen","amount2":0.29999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Seagen \/ Seattle Genetics","highestDevelopmentStatusID":"1","companyTruncated":"Seagen \/ Seattle Genetics"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SEA-TGT","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Belantamab mafodotin-blmf","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Seagen \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Belantamab mafodotin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Ladiratuzumab Vedotin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":4.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":4.2000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Merck"},{"orgOrder":0,"company":"Seagen","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Seagen \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Genmab"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Astellas"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0.28000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Oral","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Merck"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Ladiratuzumab vedotin","moa":"LIV-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seagen","amount2":3.6000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.6000000000000001,"dosageForm":"Intravenous infusion","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Seagen \/ Merck"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Tissue factor","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Pieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Cinrebafusp alfa","moa":"CD137","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Pieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ Pieris Pharmaceuticals"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seattle Genetics","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seattle Genetics"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seattle Genetics","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seattle Genetics"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"7","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Astellas Pharma Inc."},{"orgOrder":0,"company":"Seagen","sponsor":"RemeGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Disitamab Vedotin","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":2.6000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":2.6000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tucatinib","moa":"HER2 tyrosine kinase","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Takeda"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"7","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Tissue factor","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Seagen \/ Sanofi"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravescial","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Tissue factor","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Seagen Inc","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen Inc"},{"orgOrder":0,"company":"Seagen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Tissue factor","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tucatinib","moa":"HER2 TK","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Merck & Co. Inc","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Merck & Co. Inc"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Astellas"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Seagen \/ Merck"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tucatinib","moa":"HER2 TK","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Astellas"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Lava Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"LAVA-1223","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0.69999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Seagen \/ LAVA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ LAVA Therapeutics"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Astellas"},{"orgOrder":0,"company":"Seagen","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Brentuximab Vedotin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":43,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":43,"dosageForm":"Injectable\/Injection","sponsorNew":"Seagen \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Pfizer Inc"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Nurix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":3.46,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":3.46,"dosageForm":"","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seagen \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Seagen"},{"orgOrder":0,"company":"Seagen","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Brentuximab Vedotin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":43,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":43,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Pfizer Inc"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Seagen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Through the acquisition, Seagen’s medicines and expertise in ADCs will enhance Pfizer’s oncology portfolio including four approved medicines, including three ADCs, Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), and Tivdak (tisotumab ved...

                          Brand Name : Adcetris

                          Molecule Type : Large molecule

                          Upfront Cash : $43,000.0 million

                          December 14, 2023

                          Lead Product(s) : Brentuximab Vedotin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Pfizer Inc

                          Deal Size : $43,000.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.

                          Brand Name : Tukysa

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 06, 2023

                          Lead Product(s) : Tucatinib,Trastuzumab Emtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Tivdak (tisotumab vedotin) is an antibody-drug conjugate, which is investigating in phase III and met its primary endpoint of overall survival for recurrent or metastatic cervical cancer compared to chemotherapy.

                          Brand Name : Tivdak

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 22, 2023

                          Lead Product(s) : Tisotumab Vedotin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : Genmab

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Keytruda (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

                          Brand Name : Keytruda

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 22, 2023

                          Lead Product(s) : Pembrolizumab,Enfortumab Vedotin-ejf,Cisplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : Merck & Co

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The collaboration aims to advance a new class of medicines called Degrader-Antibody Conjugates (DACs) for use in cancer and will focus on an innovative approach to combine two powerful technologies to target cancer ADC and targeted protein degradation (T...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : $60.0 million

                          September 07, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Nurix Therapeutics

                          Deal Size : $3,460.0 million

                          Deal Type : Collaboration

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : TIVDAK (tisotumab vedotin) is an antibody-drug conjugate, which is investigating in phase III and met its primary endpoint of overall survival for recurrent or metastatic cervical cancer compared to chemotherapy.

                          Brand Name : Tivdak

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 04, 2023

                          Lead Product(s) : Tisotumab Vedotin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Recipient : Genmab

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.

                          Brand Name : Tukysa

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 16, 2023

                          Lead Product(s) : Tucatinib,Kadcyla

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, MMAE, utilizing Seagen's proprietary technology,for the treatment of...

                          Brand Name : Adcetris

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 14, 2023

                          Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Takeda Pharmaceutical

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Early-Stage Classical...

                          Brand Name : Adcetris

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 13, 2023

                          Lead Product(s) : Brentuximab Vedotin,Nivolumab,Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Through the acquisition of Seagen’s medicines, expertise in ADCs will enhance Pfizer’s oncology portfolio including four approved medicines, including three ADCs, Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), and Tivdak (tisotumab vedo...

                          Brand Name : Adcetris

                          Molecule Type : Large molecule

                          Upfront Cash : $43,000.0 million

                          March 13, 2023

                          Lead Product(s) : Brentuximab Vedotin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Pfizer Inc

                          Deal Size : $43,000.0 million

                          Deal Type : Acquisition

                          blank